Jump to:
Bsf Enterprise PLC Fundamentals
| Company Name | Bsf Enterprise PLC | Last Updated | 2025-11-05 |
|---|
| Industry | Biotechnology | Sector | Healthcare |
|---|
| Shares in Issue | 123.649 m | Market Cap | £3.54 m |
|---|
| PE Ratio | 0.00 | Dividend per Share | 0 |
|---|
| Dividend Yield | 0 | Dividend Cover | 0 |
|---|
| EPS | -£0.02 | EPS Growth (%) | 0 |
|---|
| PEG | 0 | DPS Growth (%) | 0 |
|---|
| Debt Ratio | 0.0116 | Debt Equity Ratio | 0 |
|---|
| Asset Equity Ratio | 1.1042 | Cash Equity Ratio | 0.1172 |
|---|
| Quick Ratio | 1.4613 | Current Ratio | 2.11 |
|---|
| Price To Book Value | 1.3464 | ROCE | 0 |
|---|
Bsf Enterprise PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Bsf Enterprise PLC Company Financials
| Assets | 2024 | 2023 | 2022 |
|---|
| Tangible Assets | £153,096.00 | £252,833.00 | £297,048.00 |
| Intangible Assets | £2.49 m | £2.49 m | £2.49 m |
| Investments | 0 | 0 | 0 |
| Total Fixed Assets | £2.64 m | £2.74 m | £2.78 m |
| Stocks | £62,392.00 | £45,811.00 | £21,855.00 |
| Debtors | £79,538.00 | £89,934.00 | £77,985.00 |
| Cash & Equivalents | £637,656.00 | £2.32 m | £1.06 m |
| Other Assets | 0 | 0 | 0 |
| Total Assets | £3.50 m | £5.26 m | £4.03 m |
| Liabilities | 2024 | 2023 | 2022 |
|---|
| Creditors within 1 year | £289,675.00 | £303,620.00 | £278,576.00 |
| Creditors after 1 year | £15,400.00 | £98,007.00 | £170,896.00 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £305,075.00 | £401,627.00 | £449,472.00 |
| Net assets | £3.19 m | £4.86 m | £3.58 m |
| Equity | 2024 | 2023 | 2022 |
|---|
| Called up share capital | £1.03 m | £1.03 m | £859,869.00 |
| Share Premium | £6.29 m | £6.29 m | £3.71 m |
| Profit / Loss | -£1.80 m | -£1.58 m | -£929,432.00 |
| Other Equity | £3.19 m | £4.86 m | £3.58 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £3.19 m | £4.86 m | £3.58 m |
| Ratios | 2024 | 2023 | 2022 |
|---|
| Debt Ratio | 0 | £0.02 | £0.04 |
| Debt-to-Equity | 0 | £0.02 | £0.04 |
| Assets / Equity | 1.1042 | 1.1042 | 1.1042 |
| Cash / Equity | 0.1172 | 0.1172 | 0.1172 |
| EPS | -£0.02 | -£0.02 | -£0.02 |
| Cash Flow | 2024 | 2023 | 2022 |
|---|
| Cash from operating activities | -£1.59 m | -£1.38 m | -£667,239.00 |
| Cashflow before financing | -£1.67 m | £1.32 m | £699,911.00 |
| Increase in Cash | -£1.68 m | £1.26 m | £701,661.00 |
| Income | 2024 | 2023 | 2022 |
|---|
| Turnover | £57,821.00 | £12,942.00 | 0 |
| Cost of sales | £84,465.00 | £71,324.00 | 0 |
| Gross Profit | -£26,644.00 | -£58,382.00 | 0 |
| Operating Profit | -£1.79 m | -£1.57 m | -£927,322.00 |
| Pre-Tax profit | -£1.80 m | -£1.58 m | -£929,432.00 |
Bsf Enterprise PLC Company Background
| Sector | Healthcare |
|---|
| Activities | BSF Enterprise PLC is a United Kingdom-based biotech company. The Company is focused on developing biotechnological solutions using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes. The Company operates through its wholly owned subsidiary, 3D Bio-Tissues Limited (3DBT), which is a clinical and cellular agriculture company engaged in producing human corneas that could help restore vision to millions of people. |
|---|
| Latest Interim Date | 25 Jun 2025 |
|---|
| Latest Fiscal Year End Date | 31 Jan 2025 |
|---|
Bsf Enterprise PLC Directors
| Appointed | Name | Position |
|---|
| 2025-02-03 | Mr. Geoffrey Robert Baker | Executive Director,Company Secretary |
| 2025-08-29 | Ms. Min Yang | Non-Executive Director,Chairman |
| 2025-02-03 | Professor Dr. Che John Connon | Executive Director,Chief Executive Officer |
Bsf Enterprise PLC Contact Details
Bsf Enterprise PLC Advisors
